about
Canine Leishmaniasis Progression is Associated with Vitamin D Deficiency.Humoral and in vivo cellular immunity against the raw insect-derived recombinant Leishmania infantum antigens KMPII, TRYP, LACK, and papLe22 in dogs from an endemic area.Transcription of Toll-Like Receptors 2, 3, 4 and 9, FoxP3 and Th17 Cytokines in a Susceptible Experimental Model of Canine Leishmania infantum Infection.Compartmentalized Immune Response in Leishmaniasis: Changing Patterns throughout the DiseaseA targeted and adjuvanted nanocarrier lowers the effective dose of liposomal amphotericin B and enhances adaptive immunity in murine cutaneous leishmaniasis.Prevalence of Leishmania infantum infection in dogs living in an area of canine leishmaniasis endemicity using PCR on several tissues and serology.Seroreactivity against raw insect-derived recombinant KMPII, TRYP, and LACK Leishmania infantum proteins in infected dogs.Anti-Leishmania IgA in urine samples from dogs with clinical leishmaniasis.Safety and efficacy of antimicrobial peptides against naturally acquired leishmaniasis.Head-to-head comparison of three vaccination strategies based on DNA and raw insect-derived recombinant proteins against Leishmania.Longitudinal analysis of cytokine gene expression and parasite load in PBMC in Leishmania infantum experimentally infected dogs.Vaccination with plasmid DNA encoding KMPII, TRYP, LACK and GP63 does not protect dogs against Leishmania infantum experimental challenge.Leishmania infantum-specific IgG, IgG1 and IgG2 antibody responses in healthy and ill dogs from endemic areas. Evolution in the course of infection and after treatment.Immune response to Leishmania infantum in healthy horses in Spain.Dynamics of Leishmania-specific immunoglobulin isotypes in dogs with clinical leishmaniasis before and after treatment.Performance of commercially available serological diagnostic tests to detect Leishmania infantum infection on experimentally infected dogs.Advantages of real-time PCR assay for diagnosis and monitoring of canine leishmaniosis.Adh expression in species of the mulleri subgroup of Drosophila.Comparison of three assays for the evaluation of specific cellular immunity to Leishmania infantum in dogsLong term improvement in the treatment of canine leishmaniosis using an antimony liposomal formulationSerological and parasitological follow-up in dogs experimentally infected with Leishmania infantum and treated with meglumine antimoniatePharmacokinetics of meglumine antimoniate after administration of a multiple dose in dogs experimentally infected with Leishmania infantumA long term experimental study of canine visceral leishmaniasisSerum cardiac troponin I concentrations in dogs with leishmaniasis: correlation with age and clinicopathologic abnormalitiesTheophylline kinetics in dog neonatesThe Ibizian hound presents a predominantly cellular immune response against natural Leishmania infectionHistological and immunohistochemical study of clinically normal skin of Leishmania infantum-infected dogsEvaluation of the efficacy of two leishmanins in asymptomatic dogsLeishmania-specific isotype levels and their relationship with specific cell-mediated immunity parameters in canine leishmaniasisDetection of Leishmania infantum DNA by fret-based real-time PCR in urine from dogs with natural clinical leishmaniosisLittle evidence of seasonal variation of natural infection by Leishmania infantum in dogs in Spain
P50
Q33794111-474E680A-04D4-4755-A36B-BAAD07535D91Q34341852-205AA0A0-C521-4166-8772-6DE31EF8AFF4Q35806436-A194B8E6-90C1-45F4-B563-BAEF9FECD0A9Q36015750-1516AA93-F40E-4C87-A1DE-9F8AF7E1DF5EQ37272354-B44F92AE-167A-46BA-A36D-1717E6E3A9DEQ39463297-521377AC-3A59-4D92-A320-10A14078A58CQ39830555-3DA0341E-E60B-4C44-8B29-26C6CD89A0B8Q40026605-FFD3EF88-B953-4464-8CE9-90095A76AADDQ40469485-10C7F2FE-79CA-4D71-9961-C8C33C30E495Q41404819-3AB13521-E355-4B50-8B89-5072C0D1A134Q42436824-A0CDD9BB-2FB0-43B4-8EE5-57CC858BE259Q43223330-DDE1E86D-B6C1-4C2D-9B60-ED1090B12D84Q43553354-35D75925-DF80-41A6-BF76-FF92BDEF546CQ44068111-D24987C7-FF29-4495-8121-C53B87832E1FQ44962478-01EBFDC1-168E-451A-BCDD-D30786F93CAEQ46129952-0D46823A-FFA5-4948-B374-01712922975CQ50946520-F256DE07-2DA3-4097-8598-2655D941565AQ52462299-E57B0272-34CB-42F1-8363-F15FB3A3D03DQ58243942-F383F850-EF09-4353-8DF9-D39D619796F9Q58852071-D219FE05-0B25-45BC-95A1-88C532904D0EQ58852077-DD9CB11D-CDAB-465A-B4C6-9AAF55D9D6FFQ58852081-24312093-40E5-4DD1-96B7-DE318ADCA16CQ61415810-8FE3EAE7-FA3E-4CE1-902B-A068EE68819BQ61758229-A5BAB421-CB69-43E6-8731-2B1B5411966FQ70672714-DDB0FDC6-66EA-4911-B5A5-9A748C478E2EQ73828239-95CF080D-7CC9-4306-9D91-5F8B976F6F90Q75204748-4C9A81AC-7A72-4209-AB30-7B4978AE2767Q77161174-701EDDE3-13D2-48CE-B678-CC72E7660F4FQ79829001-747C7248-14C4-432D-8D94-84446B1FCDFEQ80390806-95D7F849-D0A0-41D2-804E-760CD9C5D5A8Q81397952-38C10E05-BFF6-4EB7-B1E3-4C27DA10A638
P50
description
hulumtues
@sq
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Jordi Alberola
@ast
Jordi Alberola
@en
Jordi Alberola
@es
Jordi Alberola
@nl
Jordi Alberola
@sl
type
label
Jordi Alberola
@ast
Jordi Alberola
@en
Jordi Alberola
@es
Jordi Alberola
@nl
Jordi Alberola
@sl
prefLabel
Jordi Alberola
@ast
Jordi Alberola
@en
Jordi Alberola
@es
Jordi Alberola
@nl
Jordi Alberola
@sl
P214
P950
P1053
N-9695-2013
P106
P1153
6701689094
P1580
P21
P213
0000 0004 2665 7852
P214
P31
P3829
P496
0000-0002-1033-6339
P735
P7859
viaf-304119040